Personalising care of adults with asthma from Asia : a modified e-Dephi consensus study to inform management tailored to attitude and control profiles by Chisholm, Alison et al.
ARTICLE OPEN
Personalising care of adults with asthma from Asia: a modiﬁed
e-Dephi consensus study to inform management tailored to
attitude and control proﬁles
Alison Chisholm1, David B Price2,3, Hilary Pinnock4, Tan Tze Lee5, Camilo Roa6, Sang-Heon Cho7, Aileen David-Wang6, Gary Wong8,
Thys van der Molen9, Dermot Ryan4, Nina Castillo-Carandang10, Yee Vern Yong11 on behalf of the Respiratory Effectiveness Group
REALISE Asia—an online questionnaire-based study of Asian asthma patients—identiﬁed ﬁve patient clusters deﬁned in terms of
their control status and attitude towards their asthma (categorised as: ‘Well-adjusted and at least partly controlled’; ‘In denial about
symptoms’; ‘Tolerating with poor control’; ‘Adrift and poorly controlled’; ‘Worried with multiple symptoms’). We developed
consensus recommendations for tailoring management of these attitudinal–control clusters. An expert panel undertook a
three-round electronic Delphi (e-Delphi): Round 1: panellists received descriptions of the attitudinal–control clusters and provided
free text recommendations for their assessment and management. Round 2: panellists prioritised Round 1 recommendations and
met (or joined a teleconference) to consolidate the recommendations. Round 3: panellists voted and prioritised the remaining
recommendations. Consensus was deﬁned as Round 3 recommendations endorsed by 450% of panellists. Highest priority
recommendations were those receiving the highest score. The multidisciplinary panellists (9 clinicians, 1 pharmacist and
1 health social scientist; 7 from Asia) identiﬁed consensus recommendations for all clusters. Recommended pharmacological
(e.g., step-up/down; self-management; simpliﬁed regimen) and non-pharmacological approaches (e.g., trigger management,
education, social support; inhaler technique) varied substantially according to each cluster’s attitude to asthma and associated
psychosocial drivers of behaviour. The attitudinal–control clusters deﬁned by REALISE Asia resonated with the international panel.
Consensus was reached on appropriate tailored management approaches for all clusters. Summarised and incorporated into a
structured management pathway, these recommendations could facilitate personalised care. Generalisability of these patient
clusters should be assessed in other socio-economic, cultural and literacy groups and nationalities in Asia.
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INTRODUCTION
The success of treatment in any chronic disease is highly
dependent on patient behaviour, their attitude towards
the prescribed management approach and subsequent
adherence to prescribed treatment regimens. In asthma,
successful management of symptoms includes practical
trigger avoidance and implementation of (evidence-based)
therapy to maximise its potential for beneﬁt and minimise
the risk of harm. Yet large, multi-national, population-based
studies suggest that only a minority of the 17.5 million of
people with asthma in Asia (and over 300 million people
globally)1 actually achieve good control.1–4 The cost of poor
control is high, both in terms of patients’ quality of life5,6 and
their demand on healthcare resources,7–10 particularly in
Asia where equitable access to affordable, quality care continues
to be a challenge. It is therefore important to identify the
attitudinal determinants of asthma control, especially potentially
modiﬁable factors, and to intervene with affordable, targeted
approaches.11
REALISE Asia
The REcognise Asthma and LInk to Symptoms and Experience
(REALISE) Asia Study12 assessed patients’ and professionals'
perceptions of asthma control and patients’ attitudes towards
their treatment across eight participating countries in Asia:
People’s Republic of China (30%), Hong Kong (8%), Indonesia
(7%), Korea (20%), Malaysia (6%), Philippines (6%), Singapore (8%)
and Taiwan (12%). Adults (n= 2,467) aged 18–50 years receiving
treatment for physician-diagnosed asthma were randomly
sampled from established (self-reported asthma) patient panels.
They were asked (via an online survey) about their asthma
symptoms, exacerbations and treatment type, views and percep-
tions of asthma control, attitudes towards asthma management,
and sources of asthma information. Specialist and generalist
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physicians (n= 1074) completed a face-to-face and/or online
survey exploring their percpetions of the impact of asthma and
the way the disease is managed in their country; more details of
the survey scope are detailed in the accompanying online
supplement.
Echoing ﬁndings from North America and Europe,13–20 the
questionnaire revealed a mismatch in the proportion of patients
who believed they had well-controlled asthma (89%), when asked
a generic question about ‘control’, compared with the proportion
who achieved guideline-deﬁned control status (18%), assessed by
responses to speciﬁc symptom questions.12 Similarly, physicians
over-estimated the proportion of their patients who had
guideline-deﬁned control (53%). The study also revealed a
common misperception (in two-thirds of patients) that ‘control’
related to the ability to manage the acute symptoms of disease
rather than preventing symptoms and exacerbations. This was
reﬂected in the ﬁnding that over one-third of respondents
admitted to ignoring doctors’ instructions on how and when to
use prescribed treatments and almost three-quarters believed
they could manage their asthma without the help of a doctor.
These ﬁndings illustrate the important role that asthma patients’
attitudes and perceptions of their condition can have in their
receptivity to, and the acceptance and implementation of asthma
advice from healthcare professionals.
Building on the REALISE Asia ﬁndings—patient segmentation
Recognising the importance of patient attitudes in achieving a
positive patient–physician relationship and collaborative approach
to disease management, the REALISE Asia investigators used a
two-step approach to segment questionnaire responses and
characterise patients in terms of these attitudes (Figure 1). Factor
analysis was used to identify nine summary attitudinal factors and
cluster analysis to deﬁne ﬁve attitudinal groupings.21,22 Patients in
each cluster shared distinct attitudes and control proﬁles. Table 1
summarises the ﬁve attitudinal–control clusters within the REALISE
Asia population named as follows: Well-adjusted and at least
partly controlled (‘Well-adjusted’); In denial about symptoms
(‘Rejectors’); Tolerating with poor control (‘Endurers’); Adrift and
poorly controlled (‘Lost’); Worried with multiple symptoms
(Worrier’) that are described in Table 1 (attitudinal and control
characteristics) and Figure 2 (prevalence and control proﬁles).
Further detail of the cluster analysis is provided in the online
supplement.
To help realise the practical value of segmenting and character-
ising the REALISE Asia participants in terms of their asthma
attitude–control proﬁles, we used a modiﬁed electronic Delphi
(e-Delphi) procedure to generate consensus on asthma manage-
ment recommendations tailored for each of the ﬁve clusters.
RESULTS
The 11 panel members comprised nine clinicians, one pharmacist
and one Health Social Scientist working across seven countries—
ﬁve in Asia (The Philippines, Malaysia, Singapore, Hong Kong and
Korea) and two in Europe (UK and The Netherlands).
Through Rounds 1 and 2, the panellists agreed that there
was clinical utility in identifying all ﬁve attitudinal clusters as a
way to tailor asthma management approaches. On completion
of Round 3, consensus recommendations (those achieving
the support of 480% of the panel) were identiﬁed for all
attitudinal–control clusters. The consensus recommendations for
identifying and managing the different attitudinal–control clusters
are summarised in Table 2 and 3, respectively. Discussions as to
how best to implement these recommendations resulted in a
pathway illustration, Figure 3.
Figure 1. Schematic illustration of the cluster analysis approach used to identify the ﬁve attitudinal–control patient clusters within the REALISE
Asia population.22 *Being a covariate meant that the GINA-deﬁned status had an effect added to or subtracted from the factors used for
segmentation, so GINA-deﬁned status did not have an effect in itself but modiﬁed the way the other measures affected segment allocation.
Thus, segmentation model performance was improved when GINA-deﬁned control status is taken into consideration during regression
analysis.
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Identiﬁcation of Attitudinal–Control clusters
The consensus panel recommended approaches for assessing
both control and attitude in the context of the patients’ medical
and social circumstances.
Multiple options for asthma control assessment were suggested
(Table 2), including: use of validated tests (e.g., Asthma Control
Test, ACT; Asthma Control Questionnaire, ACQ; GINA-based
evaluation of control status) and structured holistic assessments
Table 1. Summary of REALISE Asia attitudinal–control clusters22
Cluster 1:
Well-adjusted
Cluster 4: Rejectors Cluster 3: Lost Cluster 4: Endurers Cluster 5: Worrier
Well-adjusted and at
least partly controlled
In Denial about
symptoms
Adrift and poorly
controlled
Tolerating with poor
control
Worried with
multiple symptoms’
Prevalencea n (%) 713 (29) 429 (18) 332 (14) 715 (29) 278 (11)
GINA control status
Controlled 34% 38% 3% 3% 0%
Partially controlled 48% 48% 19% 23% 8%
Uncontrolled 18% 14% 79% 74% 92%
Key characteristics
Level of asthma control High High Low Low Lowest
Level of conﬁdence in asthma Highest High Moderate Low Lowest
Perceived severity of asthma Mild/Less Mild/Less Moderate Moderate Severe
Frequency of seeking
information about asthma
Low Moderate High Moderate High
Level of concern about their
asthma
Low Low Moderate Moderate High
Socially conscious about
asthma
Lowest High Highest Moderate High
Descriptive summary Generally cope well
with their asthma
Asthma has minimal
impact on their daily
lives
Happy to go along
with doctor’s advice
No problem using
their inhaler,
reﬂecting carefree
attitude
Refuse to accept
asthma label
Yet to come to terms
with emotional
burden of living with
asthma
Deprioritise their
health despite some
concerns about their
asthma
High social
consciousness about
using inhaler
High level of stress
and anxiety about
their asthma
Asthma has high
impact on their daily
lives
Avoid thinking about
their health
High asthma
information seeking
frequency but do not
know where to turn
for answers
Accept their condition
and that they do not
have control over it
High acceptance of
condition means they
do not allow asthma to
have a major impact
on their daily life
Low level of
conﬁdence in
managing their asthma
Less interested in
seeking information
than other
uncontrolled patient
types
Asthma is a
constant worry on
their mind
Accept their
condition but live
with a high level of
stress and anxiety
about their asthma
Exhibit high
asthma information
seeking frequency
due to their
concerns
aWithin REALISE Asia responder population.
Figure 2. Distribution of REALISE Asia patients across Attitudinal–Control Cluster, categorised by GINA control proﬁle.22
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approaches (e.g., current smoking, inhaler technique; monitoring,
pharmacology, education and support; SIMPLES23). To evaluate
control, spirometry and peak ﬂow were proposed and (if available)
fractional exhaled nitric oxide (FeNO) assessment to detect airway
inﬂammation. Panellists agreed that selection of the appropriate
assessment approach should be guided by local healthcare
resource and informed by cultural setting.
In-depth understanding of the clinical and social context was
felt to be important in some patients. For example, assessment of
‘Lost’ patients should include evaluation of differential or co-
morbid diagnoses (e.g., comorbidity and dysfunctional breathing
assessments, potentially using lung function and FeNO testing).24
Similarly for patients classiﬁed as potential Worriers, the panellists
recommended evaluation of patients’ global anxiety (e.g., HADs,
dysfunctional breathing assessment) to assess whether the anxiety
observed is speciﬁc to the patient’s asthma, or may be a more
generalised behavioural trait.
Although there was widespread agreement among panel
members that the clusters relate to clinically recognisable groups,
it was felt that a typing tool (Figure 4) would have practical utility
in ensuring accurate assessment and categorisation of patients,
particularly in non-dedicated specialist centres.
Pharmacological management
Optimisation of pharmacological management in line with GINA
recommendations was a common theme across all clusters.
However, panellists agreed there is no ‘one-size-ﬁts-all’ approach
to pharmacological management and that optimisation needs to
be tailored to the attitudinal–control cohort, and at the individual
patient level in line with their lifestyle requirements and
preference (in keeping with the concept of personalised
medicine25).
While optimised therapy in ‘Well-adjusted’ patients may involve
dose-reduction or simpliﬁcation of the treatment regimen (i.e.,
depending on the patient’s individual control status), pharmaco-
logical optimisation in ‘Rejectors’ must take into consideration the
psychosocial determinants that result in those patients denying
their diagnosis and failing to implement prescribed treatment.
Concerns about steroid use might be addressed by reducing the
dose of inhaled corticosteroid (ICS) to the minimum required to
achieve symptom control or sometimes by use of ICS alternatives.
Suitable treatment options for ‘Rejectors’ must also be pragmatic
—recognising that these patients are likely to be intermittent
treatment users (at best) and that therapy must optimise potential
anti-inﬂammatory effects when used on this basis. In ‘Lost’ and
‘Worried’ patients, who have high levels of anxiety in relation to
their asthma, a short-term use of higher-step therapy may be
valuable to demonstrate the potential beneﬁts of treatment in the
short term before stepping down therapy to the lowest dose
possible.
Optimisation of pharmacological management is of particular
importance in ‘Endurers’ who tend to tolerate symptoms and to
lack ambition (or awareness26) as to the level of control they
should be able to achieve. Such behaviours make ‘Endurers’ a
potentially at-risk group. Panellists felt the ‘Endurer’ attitudinal–
control cluster comprises two clinically recognisable subgroups—
those who are sub-optimally controlled owing to severe and/or
difﬁcult-to-treat asthma, and those whose sub-optimal control is
due to poor implementation of their prescribed medication. The
latter includes those unable to use their therapy optimally
and those who do not use it as prescribed, either as a conscious
choice or through a lack of awareness of the potential beneﬁt of
therapy. Where adherence appears to be the principal challenge
to attainment of control, a simpliﬁed regimen and use of
once-daily therapies may be alternative options.
Pharmacological interventions should be complemented by
appropriate non-pharmacological approaches across all attitudi-
nal–control clusters.
Non-pharmacological approaches
The optimum approach for a given patient will be one that
recognises the patient’s perception of their condition and that
Table 2. Recommended tools and approaches to identify the patient clusters in clinical practice
Cluster identiﬁcation approaches Attitudinal–Control Cluster
Well-adjusted Rejectors Endurer Lost Worrier
Validated typing tool ✓ ✓ ✓ ✓ ✓
Consultation skills ✓ ✓
Open, non-judgmental, non-paternalistic
attitude to allow patients to share their
misgivings/doubts/reasons for denial
✓ ✓ ✓
Risk proﬁle and
understand concerns
Asthma control assessment (ACT, ACQ, RCP3,
GINA-based symptom control assessment)
✓ ✓ ✓ ✓ ✓
Exacerbation history/risk assessment ✓ ✓ ✓ ✓ ✓
FeNO ✓ × × ✓ ✓
Assessment of access to healthcare ✓ × × × ×
Lung function testing (spirometry, peak ﬂow) ✓ ✓ ✓ ✓ ×
Beliefs about Medicines Questionnaire (BMQ) × ✓ ✓ ✓ ✓
Morisky Medication Adherence Scale (MMAS) × ✓ ✓ × ✓
Quality of life assessment (AQLQ) × ✓ ✓ ✓ ✓
Assess medication-related adverse events × × ✓ ✓ ×
Dysfunctional breathing assessment × × × ✓ ✓
Hospital Anxiety and Depression Score (HADS) × × × ✓ ✓
Inhalation technique assessment × ✓ × × ✓
Induced sputum analysis ✓ × × × ×
Medication history review ✓ × × × ×
Assessment of patient's perceived self-efﬁcacy × × ✓ × ×
Comorbidity Assessment × × × ✓ ×
✓, speciﬁcally recommended for this patient group by the expert panel.
× , not speciﬁcally recommended for this patient group by the expert panel.
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works in partnership with them, potentially including appropriate
education and expert, non-judgmental consultation skills
(including psychological approaches). In Asian communities the
use of social networks and/or engagement of family and friends to
help ‘normalise’ the patient’s perception of their condition may be
of particular importance.
Competent consultation skills must be used to enable under-
standing of what lies beneath negative attitudes towards
healthcare (e.g., ‘Lost’ and ‘Rejectors’) or at the root of patients’
anxieties and concerns (e.g., ‘Lost’ and ‘Worriers’). Part of
optimising the patient–physician interaction is use of appropriate
language to avoid potentially worrying or alienating patients.
Terms such as ‘risk management plan’ should be avoided when
speaking with anxious ‘Lost’ or ‘Worried’ patients. Instead, these
patients would be reassured by use of empowering language and
bite-sized management plans to build conﬁdence. Phrases such as
‘asthma action plan’ may be better avoided when speaking with
‘Rejectors’ who tend not to accept their condition. Instead, the
terms patients used to describe their condition and symptoms
(e.g., ‘wheezing’ and/or ‘breathlessness’) should be adopted.
Self-management was considered to be important in all the
clusters, but needs to be tailored to patients’ individual attitudes
to their asthma. Although ‘Well-adjusted’ patients (who are most
receptive to healthcare professionals’ recommendations and have
the greatest sense of self efﬁcacy) may need little support to take
on the management of their asthma, those who are ‘Lost’ may
require self-management plans detailing smaller-scale goals to
permit regular attainment of targets to help build their conﬁdence
and may require regular follow-up after the initial consultation.
‘Endurers’, whose tolerance of their condition may result in a
failure to respond in a timely and appropriate way to a worsening
of symptoms, self-management plans with clear descriptions of
symptom worsening and necessary actions may be valuable to
support timely and appropriate access to healthcare.
DISCUSSION
Main ﬁndings
This modiﬁed e-Delphi procedure illustrates the range of clinical
management approaches required to tailor support for patients
with different attitudinal–control proﬁles in routine care. Identify-
ing patients’ attitudes is critical to successfully managing the
complexities of asthma in the widely heterogeneous population
that presents in routine daily care. The range of applicable
potential management approaches can be narrowed by clustering
patients with similar attitudes to healthcare and with similar
control status, but optimum management still needs to be tailored
to the individual determinants of each patient’s attitude and
behaviour.
Interpretation of ﬁndings in relation to previously published work
Patients’ poor perception of their level of asthma control within
REALISE Asia echo similar ﬁndings from studies in Europe and
North America.14–20 The subsequent clustering of patients by their
attitudes towards healthcare and by their control status builds on
prior work suggesting that asthma patients’ attitudes towards
their medical professionals and treatment can be used to predict
future risk of uncontrolled disease27 and that patient personality
can inﬂuence adherence to asthma medication, control and
health-related quality of life.28 The recommendations generated
by this modiﬁed e-Delphi procedure seek to apply the recom-
mendations of the 2014 GINA recommendations in terms of
optimising asthma management and targeting treatment based
on modiﬁable risk factors, patient preference and practical issues
—optimisation of medication effectiveness by addressing inhaler
technique and adherence.29T
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Strengths and limitations of this study
The e-Delphi panel comprised Asian and European healthcare
professionals and an Asian pharmacist and social scientist to
ensure the recommendations recognised and reﬂected cultural
and social nuances speciﬁc to the source population and care
settings (e.g., 4 of the 8 countries that participated in REALISE Asia
were represented in the panel), but also retained validity and
potential applicability in other geographies and healthcare
settings.
All eleven panellists contributed to all three of the mandatory
elements of the modiﬁed e-Delphi process (i.e., the email-based
interaction by which initial recommendations were sourced and
subsequently voted for and prioritised). Partial involvement in the
optional elements of the process (i.e., the elements that ‘modiﬁed’
the process from a standard Delphi) reﬂected the panellists’ prior
experience of Delphi procedures (with Round 1.2 seeking to
standardise the knowledge of all panellists) and panellists'
geographical location (with the Round 2.2 meeting venue and
time zone preferential to the majority Asian panellists). The overall
retention of all panel members suggests there was broad
agreement among panellists throughout the process, irrespective
of their speciality discipline and geographical origin. Internal
agreement was further strengthened by the iterative reﬁnement
of the recommendations through the consensus process.
The REALISE Asia recruitment criteria (i.e., asthma patients aged
18–50 years with physician-diagnosed asthma who had received
at least two asthma prescriptions in the 2 preceding years and
who had access to social media) may have resulted in some
patients with intermittent asthma (or potentially misdiagnosed as
having asthma) being included in the source population. However,
all panellists felt the attitudinal–control clusters derived from
the REALISE Asia study data were recognisable and relevant
irrespective of the region, or the healthcare settings, in which they
practiced. In addition, the panellists agreed that the distribution
of patients between the cohorts may vary in different countries
(see Supplementary Information for the distribution of cluster
prevalence within the REALISE Asia participant countries).
However, between-country differences were not felt to be a
concern as societal attitudes towards chronic disease and
healthcare interventions will vary between nations. Within that
context, the recognition of the ﬁve clusters by physicians working
in all eight participating countries offers conﬁdence in the validity
of their existence, both within Asia and likely beyond.
Although the attitudinal cohorts were deﬁned to be distinct
(i.e., mutually exclusive) as a result of their unique control status
and attitude proﬁles, it was noted by panellists that some
Figure 3. Management Pathway Algorithm for the attitudinal–control cluster consensus recommendations. *ACT, RCP3, GINA-based symptom
control, SIMPLES; Yspirometry, peak ﬂow, FeNO; ACT, asthma control test; ACQ, asthma control questionnaire; Acronyms, AQLQ, asthma
quality of life questionnaire; BMQ. belief about medicines questionnaire; CBT, cognitive behavioural therapy; HADS, Hospital Anxiety and
Depression Scale; MMAS, Morisky Medication Adherence Scale; RCP3, Royal College of Physicians; SIMPLES, Smoking, Inhaler technique.
Monitoring, Pharmacology, Lifestyle, Education, Support.
Figure 4. Attitudinal cohort proﬁling tool developed for use in
clinical practice by the REALISE Asia investigators22. Patients must
answer Agree/Disagree to each statement, 1–10. The patient's
physician must indicate whether the patient has: controlled; partly
controlled or uncontrolled asthma. Once complete, the patient's
attitudinal classiﬁcation is automatically generated.
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of the key characteristics (e.g., demonstration of health seeking
behaviours) were common to more than one cluster (Table 1).
The multifaceted cluster typing tool that was developed by the
REALISE Asia investigators may assist in the accurate categorisa-
tion of patients.
The patient cluster identiﬁed by attitudinal–control cluster
typing should not be considered to be an intrinsic patient
characteristic. Patients' attitudes to healthcare can and do change
over time as cognitive function varies (child to adult; adult to
elderly) and levels of trust in healthcare alters as a result of patient
experience and changing levels of care. Thus a patient may move
from the ‘Lost’ cluster to the ‘Well-adjusted’ cluster as they gain
more trust in healthcare. Indeed, moving towards the improved
control proﬁle of Well-adjusted patients should be management
goals for the ‘Lost’, ‘Worrier’ and ‘Endurer’ clusters. Thus
attitudinal–control classiﬁcation should be assessed at regular
intervals (e.g., at the time of annual asthma reviews) to ensure any
transitions between categories can be identiﬁed and future
interventions adjusted to optimise their relevance to the current
disease state and mind-set of the patient.
In addition, there may be other patient clusters present in
routine care (both in Asia and beyond) that were not represented
in the REALISE Asia population (e.g., those without access to the
internet and/or inactive on social media and so excluded from the
source population). Indeed, it is acknowledged that the require-
ment for REALISE Asia participants to be adult asthma patients
within with access to internet-based social media may reduce
external validity of the clusters, or at least the relative prevalence
of each. At the time of writing, there remain wide variations in
access to the Internet and social media across Asia, although
China is now the largest base of Internet users and, along with
Japan, beneﬁts from some of the fastest Internet speeds globally.
Advances in Internet infrastructure, uptake and affordability in
access in the region also see Malaysia, the Philippines, and
Indonesia now being ranked among the top 15 countries globally
in terms of Facebook users worldwide (with the Indonesia and the
Philippines making the top 10 for Twitter).30
Implications for future research, policy and practice
These recommendations formalise the traditional primary-care
approach in which a patient with a medical condition is assessed
and understood in the context of their clinical, psychological and
social status.
The recommendations proposed by the panellists are
intended to complement (not replace) pre-existing asthma
recommendations. In the 2014 update, GINA recommended
greater evaluation of patient risk and management of modiﬁable
risk factors to complement (and guide) optimisation of step-wise
pharmacological management. The panel’s recommendations
support the GINA approach by providing guidance as to how
pharmacological management approaches can be best tailored
and optimised in routine care, including suggestions as to how
best to engage and modify negative healthcare attitudes that can
be a barrier to medication adherence and treatment outcomes.
While the majority of the consensus management approaches are
in line with GINA recommendations for all patients, some of the
approaches are only speciﬁcally detailed for a subset of the ﬁve
clusters. This reﬂects the panel’s view that these approaches were
of particular relevance in the speciﬁed clusters, not that they
would be inappropriate in a wider context (Table 3).
In Asian adult asthma patients, key modiﬁers of management
approaches will include consideration of patients’ access to
affordable high-quality healthcare, cultural attitudes and beliefs
about medicines, literacy and health literacy, and a common
dependence on support from family networks and social groups.
Selection of appropriate objective assessment tools will be
informed by the availability of local language translations and
by whether they have been validated for use in a local/relevant
population.
The potential risks of this management approach lie in too
rigorous an application of the classiﬁcation. Although a validated
typing tool that allocates patients to one of the ﬁve clusters was
felt useful to help direct management approaches, competent
consultation skills remain key to determining the underlying
drivers of an individual patients’ presenting characteristics was
necessary to tailor those approaches to optimal effect.
These realities again highlight the critical role that close
patient–physician interaction, good communication and a holistic
approach to patient assessment hain capturing the nuances of an
individual patient’s condition, the changes over time and the
speciﬁc ways in which general management recommendations
should be tailored at the individual level.
CONCLUSION
The modiﬁed e-Delphi procedure successfully reached consensus
recommendations from a multidisciplinary international panel of
respiratory, pharmacology and health sciences experts working
across a range of cultural, regional and healthcare settings. The
recommendations offer a pragmatic approach to complement
guideline-recommended management approaches. They aim to
serve as an additional tool for guiding physicians in the optimum
care of their patients with asthma. Their interpretation and
application in clinical practice must be guided by thoughtful
interpretation in the context of the individual patient’s experience
and needs and changes over time. Further work is required to
assess the utility and applicability of these complementary
management recommendations for each patient cluster and
across geographical and cultural regions.
MATERIALS AND METHODS
Modiﬁed e-Delphi procedure
The Delphi procedure is a structured research technique used to reach
consensus via mail/email (Delphi/e-Delphi) on a speciﬁc topic among a
panel of experts through feedback of information and iteration.31,32
The process is complete when consensus is reached.33 It has been used in
several recent respiratory studies and research activities, including the
Figure 5. Modiﬁed e-Delphi procedure, summary of the mandatory
(traditional) and optional (modiﬁed) rounds undertaken by the
panellist and panellist participation at each step.
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International Primary Care Respiratory Group (IPCRG) as a structured
approach to prioritisation of primary-care research needs.34
The modiﬁed Delphi procedure used to reach consensus within this
study differed from the traditional procedure in that it incorporated two
additional, complementary discussion steps (Figure 5).
Panel selection
For this modiﬁed e-Delphi procedure, the Respiratory Effectiveness Group
(REG; www.effectivenessevaluation.org) invited investigators from the
REALISE Asia and REALISE Europe studies13,20 and a number of Asian
and European representatives from the REG collaborator group.
Consensus and feedback
The procedure consisted of ﬁve steps across three distinct rounds—Round
1: (i) circulation of brieﬁng materials and a questionnaire requesting open,
free text management recommendations, and (ii) participation in an
optional complementary brieﬁng call (NC, TTL, YVY, DP, ADW)); Round
2 required panellists to (i) review and priority scoring Round 1
recommendations, and (ii) participate in a panel discussion to consolidate
recommendations (TTL, HP, DP, NC, CR, ADW)). The ﬁnal round, Round 3,
involved the ﬁnal scoring and prioritisation of the remaining
recommendations (Figure 5).
Round 1 (March 2015)
All panellists received a letter explaining the rationale and context for the
project and a written summary of key characteristics of the ﬁve attitudinal–
control clusters identiﬁed within REALISE Asia. They were also sent a
questionnaire asking them to indicate whether they believed identiﬁcation
of each cohort was clinically useful and invited to provide free text
recommendations for each patient cluster to (a) identify patients with the
attitude/control characteristics represented by that cluster, and for
tailoring (b) pharmacological and (c) non-pharmacological approaches to
managing these patients (Figure 5, Round 1.2; Supplementary Table 1a–e).
All panel members were also invited to join an optional teleconference
to address any questions they had concerning the methodology and
speciﬁcally to clarify the description of the clusters (Figure 5, Round 1.1;
NC, TTL, YYV, DP joined).
Round 2 (April 2015)
Round 2 involved two distinct steps—(i) independent scoring of Round 1
recommendations (via email), and (ii) sub-panel review, discussion and
consolidation of recommendations (face-to-face meeting or virtual/
telephone participation).
For the independent scoring phase (Figure 5, Round 2.1), each panel
member received a collated summary of the free text recommendations
collected during Round 1 (Supplementary Table 2a–c). For each cluster,
panellists were requested to (i) indicate their agreement/disagreement
with each recommendation and (ii) highlight and score the top three
recommendations within each recommendation subset (identiﬁcation,
pharmacological and non-pharmacological recommendations).
Once the independent scoring phase was complete, the research
coordinator collated and combined all scores for group review and
discussion (Supplementary Table 3a–e). Panellists attending the VIII World
Asthma Allergy and COPD Forum in Singapore (NC, DP, ADW, TTL) met
face-to-face to review and discuss the ranked recommendations with a
view to reducing the number of individual items and to work towards
consensus (Figure 5, Round 2.2). Panellists not attending the Forum were
invited to join remotely via teleconference (CR, HP joined). During the sub-
panel discussions, similar recommendations were combined under a wider,
more encompassing generic heading with the more speciﬁc original
recommendations listed as examples beneath. In addition, recommenda-
tions that failed to receive majority endorsement (deﬁned as endorse-
ment/support from more than half of the panel, i.e., ≥ 6 of 11 possible
votes) were removed.
Round 3 (May–July 2015)
Final consensus was reached by circulating the consolidated Round 2
recommendations to all panellists and inviting them to vote for, and
prioritise, the remaining recommendations for each cluster. Final
consensus was deﬁned as recommendations receiving Round 3 votes by
450% of panel members and the highest priority recommendations were
those receiving the highest total priority score.
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